Legato Biologics’ uniQon™ technology delivers a nearly “true” site-specific conjugation solution, offering precise control over the drug-to-antibody ratio (DAR), resulting in optimal therapeutic performance. This proprietary conjugation platform ensures high precision, enabling the attachment of payloads at predefined sites with exceptional accuracy. By achieving a controlled DAR, uniQon™ enhances the therapeutic index of Antibody-Drug Conjugates (ADCs), maximizing their efficacy while minimizing off-target catabolism that can lead to unwanted toxicity.
A key advantage of uniQon™ lies in its consistency, ensuring reproducible ADC production with uniform product profiles across batches. This level of control significantly reduces variability, which is critical for regulatory approval and large-scale manufacturing. The platform achieves this by incorporating proprietary uniQon™ sequences, which are specifically recognized by transglutaminase (TGase), an enzyme that facilitates precise conjugation. The quantity of these sequences, or tags, can be strategically designed to achieve the desired DAR, offering unparalleled flexibility and control in ADC development.
To validate the true site-specific nature of the conjugation, rigorous analytical techniques such as High-Performance Liquid Chromatography (HPLC) and Liquid Chromatography-Mass Spectrometry (LC/MS) have been employed. These analyses confirm that uniQon™ delivers nearly homogeneous conjugated products with few side products. The high degree of batch-to-batch consistency and resulting improved therapeutic predictability provide a competitive edge in the ADC landscape, addressing common challenges associated with traditional conjugation methods.
In summary, Legato Biologics’s uniQon™ technology provides an innovative, scalable, and cost-effective solution for site-specific ADC conjugation. With its high precision, improved efficacy, and consistent manufacturing outcomes, uniQon™ is a transformative advancement that empowers biopharmaceutical companies to develop next-generation ADCs with superior therapeutic profiles and regulatory compliance.
